STOCKHOLM, Sweden, 11 November 2026. KDventures AB (publ) (Nasdaq Stockholm: KDV) today announces that its portfolio company SVF Vaccines has entered into a research collaboration with Orexo AB (publ), a Swedish pharmaceutical company, to investigate whether Orexo’s proprietary AmorphOX® technology can be used to develop stable powder-based formulations of lipid nanoparticle-encapsulated messenger RNA (LNP-mRNA) vaccines.
The collaboration combines SVF Vaccines’ expertise in vaccine development and antigen design with Orexo’s proprietary powder-based drug delivery technology. The initial proof-of-concept programme will evaluate whether LNP-mRNA formulations can be spray dried using AmorphOX® while preserving critical nanoparticle properties and functional mRNA activity. The first phase will focus on in vitro feasibility, with further development to be considered based on the results.
Lipid nanoparticles protect mRNA and enable its delivery into cells, but maintaining the stability of both the mRNA and its lipid carrier presents challenges for storage and distribution. Successful development of stable powder-based formulations could simplify handling and transportation of future mRNA vaccines and potentially enable alternative routes of administration, including needle-free intranasal delivery.
“The collaboration with Orexo represents another step in SVF Vaccines’ efforts to advance its vaccine technologies through strategic partnerships. While the initial studies are exploratory, positive results could create new opportunities for the development and administration of future mRNA vaccines,” says Viktor Drvota, CEO of KDventures.
KDventures holds a direct ownership in SVF Vaccines of 33 percent.